| For: | Feng XC, Liu FC, Chen WY, Du J, Liu H. Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy. World J Gastrointest Oncol 2023; 15(4): 617-631 [PMID: 37123054 DOI: 10.4251/wjgo.v15.i4.617] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v15/i4/617.htm |
| Number | Citing Articles |
| 1 |
Yijie Zhou, Zhengpeng Chen, Meixiu Lu, Xingling Wan, Ruxin Nong, Xiaoyue Liu, Shutong Dong, Yuxiang Lu, Chengyuan Su. Effect of salinity on the operational efficiency, microbial community, and metabolism of a bioelectrochemical-granular sludge coupled system for treating sulfate wastewater. Journal of Water Process Engineering 2024; 57 doi: 10.1016/j.jwpe.2023.104737
|
| 2 |
RIYAD F. ALZHRANI, LAMA BINOBAID, ABDULAZIZ A. ALORAINI, MESHAL S. ALSAHLI, AHMED H. BAKHEIT, HANADI H. ASIRI, SABRY M. ATTIA, ALI ALHOSHANI, GAMALELDIN I. HARISA. ERLNs augment simultaneous delivery of GFSV into PC-3 cells: Influence of drug combination on SDH, GPX-4, 5α-RD, and cytotoxicity. Oncology Research 2025; 33(4) doi: 10.32604/or.2024.054537
|
| 3 |
Gamaleldin I. Harisa, Ahmed H. Bakheit, Samiyah Alshehri, Sabry M. Attia, Mohamed S. M. Attia. Chitosan-enclosed SLN improved SV-induced hepatocellular cell carcinoma death by modulation of IQGAP gene expression, JNK, and HDAC activities. Molecular Biology Reports 2024; 51(1) doi: 10.1007/s11033-024-09757-2
|
| 4 |
Maria Kopsida, Lotta Regtop, Hans Lennernäs, Mikael Hedeland, Femke Heindryckx, Mikael K.R. Engskog. Mapping the polar metabolome in Huh-7 liver cancer cells reveal the role of atorvastatin in enhancing chemotherapeutic efficacy of doxorubicin. Journal of Pharmaceutical and Biomedical Analysis 2025; 265 doi: 10.1016/j.jpba.2025.117012
|
| 5 |
Chenfang Zhang, Dan Zhang, Xin Wen, Shui Liu. Drug resistance mechanisms of immunotherapy and translational strategies for reversing resistance for hepatocellular carcinoma: from bench to bedside. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1808109
|
| 6 |
Yuxin Wang, Lu Li, Fanqi Qu, Tao Hua, Chu Chen, Lu Yang, Rong Jiang, Xuanke Liu, Pu Cheng, Hongxiao Min, Yixiang Wang, Xiucheng Pan, Dexu Sun, Renxian Tang, Ruyu Liu, Hongjuan You, Fanyun Kong. ALDH2 inhibits FASN stabilization via the E3 ligase CBL to suppress lipid accumulation and liver cancer development. Biology Direct 2026; 21(1) doi: 10.1186/s13062-026-00806-3
|
| 7 |
Hilal Tosun, Habibe Karadas, Hamid Ceylan. Bioinformatics‐based identification of hepatocellular carcinoma‐associated hub genes and assessment of the restorative effect of tannic acid in rat liver exposed to monosodium glutamate. Cancer Medicine 2024; 13(12) doi: 10.1002/cam4.7404
|
| 8 |
Dennis Kwabiah, Veerababu Nagati, Manish K. Tripathi. Transcription factor YBX1 orchestrates drug resistance and tumor progression in HCC. Drug Discovery Today 2025; 30(9) doi: 10.1016/j.drudis.2025.104439
|
| 9 |
Qianqian Shi, Yu Bai, Jiayuan Wang, Mengyao Ru, Kun Zhang, Yan Guo, Zhantao Bai, Lan Shen. The tumor suppressor NDRG2 promotes ACC1 proteasomal degradation and inhibits de novo lipogenesis in hepatocellular carcinoma. Molecular Biomedicine 2026; 7(1) doi: 10.1186/s43556-026-00451-2
|
| 10 |
Bislom C. Mweene, Kit Neikirk, Sepiso K. Masenga, Suraj Thapliyal, Andrea Marshall, Prasanna Venkhatesh, Prasanna Katti, Amber Crabtree, Berwin Singh Swami Vetha, Claude Albriton, Joyonna Gamble-George, Benjamin Rodriguez, Annet Kirabo, Mohd Mabood Khan, Antentor Hinton. Mitochondrial dysfunction in hepatocellular carcinoma: Linking aging hallmarks to organelle dynamics, metabolism, and disease progression. Aging Advances 2026; doi: 10.4103/AGINGADV.AGINGADV-D-25-00047
|
| 11 |
RIYAD F. ALZHRANI, ABDULRAHMAN A. ALLUHAIDAN, SULTAN M. ALAMRI, GAMALELDIN I. HARISA, AHMED H. BAKHEIT, HANADI H. ASIRI, SABRY M. ATTIA. Chitosan capped-NLCs enhanced codelivery of gefitinib and simvastatin into MDR HCC: impact of compositions on cell death, JNK3, and Telomerase. Oncology Research 2025; 33(2) doi: 10.32604/or.2024.053337
|
| 12 |
Syifaus Shodry, Yuliono Trika Nur Hasan, Iwal Reza Ahdi, Zulvikar Syambani Ulhaq. Gene targets with therapeutic potential in hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2024; 16(12): 4543-4547 doi: 10.4251/wjgo.v16.i12.4543
|
| 13 |
Jiao Wang, Chengyu Liu, Ronghua Hu, Licheng Wu, Chuanzhou Li. Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1324140
|
| 14 |
Zong Wu, Yixiu Wang, Bingran Yu, Ruobing Yu, Mo Chen, Zhiwen Chen, Jijun Shan, Zhiwen Ding, Jiaxi Li, Xin Jin, Yixin Chen, Longrong Wang, Hongxu Zhu, Weiping Zhu, Qi Pan, Ti Zhang, Yongfa Zhang, Lei Lv, Lu Wang, Yiming Zhao. Potentiating BSEP-mediated bile acid efflux reverses first-line tyrosine kinase inhibitor resistance in hepatocellular carcinoma. Cancer Letters 2026; 648 doi: 10.1016/j.canlet.2026.218453
|
| 15 |
Xiaoju Huang, Mengmeng Wang, Dan Zhang, Chen Zhang, Pian Liu. Advances in Targeted Drug Resistance Associated with Dysregulation of Lipid Metabolism in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2024; doi: 10.2147/JHC.S447578
|
| 16 |
Zhouwei Zhan, Xiaojie Wang, Muqun He, Shenghong Wei, Jiami Yu, Hanchen Zheng, Qiaoting Hu, Bijuan Chen, Sha Huang, Zengqing Guo. Identification of plasma lipidomic biomarkers for prognostic stratification in advanced gastric cancer treated with PD-1 inhibitor plus chemotherapy. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1714472
|
| 17 |
Mingkang Yu, Di Yang, Xiuli Chen, Yuling Yang, Bingqiang Zhang, Xinxin Jiang, Lijie Xing, Yuxuan Yang, Yani Sun, Ning Li. Metabolic reprogramming in cancer: dysregulation of glucose, lipid, and amino acid pathways and therapeutic opportunities. Molecular Biomedicine 2026; 7(1) doi: 10.1186/s43556-026-00427-2
|
| 18 |
Yuanyuan Yang, Peipei Zhao, Hepu Chen, Yixuan Tu, Yujia Zhou, Xu Liu, Lyly Sreang, Zhigang Zhou, Jian Tu. Novel Strategies against Hepatocellular Carcinoma through Lipid Metabolism. Oncology Research 2025; 33(11) doi: 10.32604/or.2025.066440
|